

were the resolved by SDS-PAGE, and exposed to film. A. Top left and right panels; samples analyzed under non-reducing conditions. B. Lower left and right panels; samples analyzed under reducing conditions. Top and bottom left panels; Cell extracts. Top and bottom right panels; Conditioned media extracts. The relative mobility of the 55 kd monomeric and 100 kd dimeric forms of OPG are indicated by arrowheads.

*B7*  
Please replace the previously submitted Sequence Listing with the Sequence Listing attached hereto.

IN THE CLAIMS

Please cancel Claims 1-60 without prejudice and add the following new claims.

61. (new) An antibody or fragment thereof which binds an epitope comprising at least a portion of the amino acid sequence of SEQ ID NO:121.

62. (new) The antibody or fragment of Claim 61 which binds to an OPG polypeptide consisting of the amino acid sequence of SEQ ID NO:121.

63. (new) An antibody or fragment thereof which binds an epitope comprising at least a portion of the amino acid sequence of SEQ ID NO:123.

*B9*  
64. (new) The antibody or fragment of Claim 63 which binds to an OPG polypeptide consisting of the amino acid sequence of SEQ ID NO:123.

65. (new) An antibody or fragment thereof which binds an epitope comprising at least a portion of the amino acid sequence of SEQ ID NO:125.

66. (new) The antibody or fragment of Claim 65 which binds to an OPG polypeptide consisting of the amino acid sequence of SEQ ID NO:125.

67. (new) The antibody or fragment of Claim 65 which binds to an OPG polypeptide consisting of residues 22-401 inclusive of SEQ ID NO:125.

68. (new) The antibody or fragment of Claim 65 which binds to an OPG polypeptide consisting of residues 22-185, 22-189, 22-194 or 22-201 inclusive as shown in SEQ ID NO:125.

69. (new) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a monoclonal antibody.

70. (new) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a chimeric antibody.

71. (new) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a CDR-grafted antibody.

72. (new) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a humanized antibody.

73. (new) The antibody of Claims 61, 62, 63, 64, 65, 66, 67 or 68 which is a human antibody.

74. (new) A method for detecting the presence of OPG in a biological sample comprising:  
incubating the sample with the antibody or fragment of Claims 61, 62, 63, 64, 65, 66, 67 or  
68 under conditions that allow binding of the antibody to OPG; and  
detecting the bound antibody.

75. (new) A method for removing OPG from a biological sample comprising:  
contacting the sample with the antibody or fragment of Claims 61, 62, 63, 64, 65, 66, 67 or  
68 under conditions that allow binding of the antibody to OPG; and  
removing the antibody from the sample.